Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Questcor Rises After Strong Shipping Numbers: Los Angeles Mover

Sept. 7 (Bloomberg) -- Questcor Pharmaceuticals Inc. climbed to its highest value in almost two months after the drugmaker said shipments of its Acthar multiple sclerosis injection rose 33 percent last month.

Questcor rose 3.3 percent to $51.97 at 4 p.m. New York time, its highest closing price since July 9.

Shipments of Acthar climbed to 2,190 vials in August, 540 more than a month earlier, the company said in a regulatory filing today. Acthar is approved for treating multiple sclerosis relapses, infantile spasms and damaged kidneys.

“We would be buying Questcor related to these Acthar numbers,” said Marko Kozul, a San Francisco-based analyst for Leerink Swann, in a note to investors today. The shipping trends were ahead of estimates and suggests a strong third quarter, he wrote.

Kozul reiterated his outperform rating and a valuation of $55 to $58.

To contact the reporter on this story: Elizabeth Lopatto in New York at elopatto@bloomberg.net.

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net.

Please upgrade your Browser

Your browser is out-of-date. Please download one of these excellent browsers:

Chrome, Firefox, Safari, Opera or Internet Explorer.